- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03765762
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
January 8, 2021 updated by: Alkahest, Inc.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability and potential cognitive benefit of GRF6019, a human plasma protein fraction.
GRF6019 or placebo will be administered intravenously to subjects with severe Alzheimer's disease every day for 5 consecutive days.
The total study duration for each subject is approximately 9 weeks.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Gilbert, Arizona, United States, 85297
- Cognitive Clinical Trials
-
Mesa, Arizona, United States, 85209
- Cognitive Clinical Trials
-
Phoenix, Arizona, United States, 85037
- Cognitive Clinical Trials
-
-
California
-
San Diego, California, United States, 92103
- Pacific Research Network
-
-
Florida
-
Edgewater, Florida, United States, 32132
- Riverside Clinical Research
-
-
New Jersey
-
Toms River, New Jersey, United States, 08755
- Bio Behavioral Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of probable AD according to the National Institute on Aging-Alzheimer's Association (NIA-AA) Criteria
- MMSE Score 0-10 inclusive
- Modified Hachinski Ischemia Scale (MHIS) score of 4 or less
- Provided a signed and dated informed consent form (either the subject and/or subject's legal representative)
Exclusion Criteria:
- Evidence of clinically relevant neurological disorder(s) other than probable AD
- History of blood coagulation disorders or hypercoagulability; any concurrent use of an anticoagulant therapy. (e.g., heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors). Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable.
- Unstable coronary heart disease, e.g. myocardial infarction or severe or unstable angina in the 6 months prior to dosing.
- Moderate to severe congestive heart failure (New York Association Class III or IV).
- Poorly controlled high blood pressure (systolic blood pressure of 160 mmHg or higher and/or diastolic blood pressure of 100 mmHg or higher) despite treatment during the 3 months prior to dosing, or treatment refractory high blood pressure, defined as treatment requiring 3 or more antihypertensives from different classes.
- Prior hypersensitivity reaction to any human blood product or intravenous infusion; any known clinically significant drug allergy.
- Treatment with any human blood product, including transfusions and intravenous immunoglobulin, during the 6 months prior to screening.
- History of immunoglobulin A (IgA), haptoglobulin or C1 inhibitor deficiency; stroke, anaphylaxis, or thromboembolic complications of intravenous immunoglobulins.
- Hemoglobin <10 g/dL in women; and <11 g/dL in men.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GRF6019
Subjects will receive intravenously 250 mL of GRF6019 each day for 5 consecutive days.
|
GRF6019 for IV infusion
|
Placebo Comparator: Placebo
Subjects will receive intravenously 250 mL of placebo each day for 5 consecutive days.
|
Placebo for IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Treatment-emergent Adverse Events (Safety)
Time Frame: 5 weeks
|
Number of Subjects with at Least One Treatment-emergent adverse event by MedDRA preferred term and grouped by MedDRA System Organ Class
|
5 weeks
|
Tolerability of GRF6019
Time Frame: 5 weeks
|
Tolerability of treatment defined by the number of subjects completing 4 weeks of study after receiving 5 daily infusions
|
5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Mini-Mental State Examination (MMSE) Score
Time Frame: Baseline and 5 weeks
|
Mean change from Baseline to 5 Weeks in the Mini-Mental State Examination (MMSE) score.
The MMSE consists of 5 components: orientation to time and place, registration of 3 words, attention and calculation, recall of 3 words, and language.
The scores from the 5 components are summed to obtain the overall MMSE total score.
The MMSE total score can range from 0 to 30, with higher scores indicating better mental status.
|
Baseline and 5 weeks
|
Severe Impairment Battery (SIB) Total Score
Time Frame: Baseline and 5 weeks
|
Mean change from baseline in the SIB total score.
The SIB assesses cognition; test questions measure orientation, attention, language, praxis, visuospatial perception, construction, memory, orientation to name, and social interaction.
There are 57 items and the range of possible scores is 0-133.
Lower scores indicate greater cognitive impairment.
|
Baseline and 5 weeks
|
Alzheimer's Disease Cooperative Study Group Activities of Daily Living Inventory for Severe Alzheimer's Disease (ADCS-ADL-Severe)
Time Frame: Baseline and 5 weeks
|
Mean change from baseline in the ADCS-ADL-Severe score.
The ADCS-ADL-Severe contains 19 items covering physical and mental functioning and independence in self-care and assesses the competence in performing basic activities of daily living.
The scores range from 0 to 54, with higher scores indicating less functional impairment.
|
Baseline and 5 weeks
|
Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change Plus Caregiver Input (ADCS-CGIC)
Time Frame: Baseline and 5 weeks
|
Mean ADCS-CGIC score.
A CGIC score is based on clinicians' observations of change in the subject's cognitive, functional, and behavioral performance since the beginning of a trial.
The ADCS-CGIC is a rating of change and not of severity.
It provides a semi structured format to enable clinicians to gather necessary clinical information from both the subject and informant to make a global impression of change.
After completing the interviews, the clinician records the clinical impression of change on a 7-point Likert-type scale (from marked improvement to marked worsening).
A score of 4 indicates no change, while scores > 4 indicate worsening and scores < 4 indicate improvement.
|
Baseline and 5 weeks
|
Neuropsychiatric Inventory Nursing Home (NPI-NH) Total Score
Time Frame: Baseline and 5 weeks
|
Mean change from Baseline to 5 weeks in the NPI-NH total score.
The NPI-NH is a questionnaire that quantifies behavioral changes in dementia in nursing home patients and evaluates 12 behavioral domains (Delusions, Hallucinations, Agitation/Aggression, Depression/Dysphoria, Anxiety, Elation/Euphoria, Apathy/Indifference, Disinhibition, Irritability/Lability, Aberrant Motor Behavior, Sleep and Nighttime Behavior Disorders, Appetite/Eating Changes).
For each of the 12 behavioral domains the Frequency (scale:1=occasionally to 4=very frequently) is multiplied by the Severity (scale:1=Mild to 3=Severe) to obtain a domain score (frequency x severity), with a possible summed total score of 0 to 144.
Lower scores correspond to less severity.
A negative change score from baseline indicates improvement.
|
Baseline and 5 weeks
|
Neuropsychiatric Inventory (NPI) Caregiver Total Score
Time Frame: Baseline and 5 weeks
|
Mean change from Baseline to 5 Weeks in NPI Total Score.
NPI is based on responses from the informed caregiver during an interview.
It consists of 12 sub-domains (Delusions, Hallucinations, Agitation/Aggression, Dysphoria/Depression, Anxiety, Euphoria/Elation, Apathy/Indifference, Disinhibition, Irritability/Lability, Aberrant Motor, Nighttime Behavior, Appetite/Eating).
For each of the 12 behavioral domains the Distress (scale:0=Not distressing at all to 5=Extreme) is multiplied by the Severity (scale:1=Mild to 3=Severe) to obtain a domain score (distress x severity), with a possible summed total score of 0 to 180.
Lower scores correspond to less severity.
A negative change score from baseline indicates improvement.
|
Baseline and 5 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Alkahest Program Physician, Alkahest, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2019
Primary Completion (Actual)
December 17, 2019
Study Completion (Actual)
December 17, 2019
Study Registration Dates
First Submitted
November 29, 2018
First Submitted That Met QC Criteria
December 4, 2018
First Posted (Actual)
December 5, 2018
Study Record Updates
Last Update Posted (Actual)
January 27, 2021
Last Update Submitted That Met QC Criteria
January 8, 2021
Last Verified
May 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Alkahest study 6019-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Alzheimer Disease
-
Medivation, Inc.PfizerTerminatedModerate to Severe AlzheimerChile, United Kingdom
-
Institut de Sante Publique, d'Epidemiologie et...CompletedAlzheimer Disease or Associated Disorder | Mild to Moderately Severe DementiaFrance
-
Regenera Pharma LtdSyneos HealthCompletedHealthy Volunteers | Moderate to Severe Alzheimer PatientsCanada
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Eisai Inc.PfizerWithdrawnSevere Alzheimer's DiseaseUnited States
-
Hyundai Pharmaceutical Co., LTD.RecruitingModerate-to-severe Alzheimer's DiseaseKorea, Republic of
-
Eisai Inc.PfizerCompletedMild to Severe Alzheimer's DiseaseUnited States
-
Samsung Pharmaceutical Co., Ltd.Not yet recruitingModerate to Severe Alzheimer's Disease
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States